Pos0576 Outcomes of Covid-19 Infection in Patients With Autoimmune Rheumatic Diseases Compared to the General Population: A Nationwide Population-Based Retrospective Study Using the Korean Health Insurance Review and Assessment Service (Hira) Database

Background: There is concern that patients with autoimmune rheumatic diseases (AIRD) are at an increased risk of infection and complications, related to the nature of their disease and the use of immunosuppressive therapies. Objectives: We aimed to evaluate clinical characteristics and outcomes of COVID-19 in patients with AIRD compared to the general population. Methods: In this nationwide population-based retrospective study, we investigated the data of AIRD patients and propensity score-matched the general population with laboratory-confirmed COVID-19, aged ≥ 18 years using database of the Korean Health Insurance Review and Assessment Service (HIRA) claim records. Comorbidities and medications used were identified using HIRA codes, and outcomes including requiring oxygen therapy, mechanical ventilator, cardiopulmonary resuscitation (CPR), or extracorporeal membrane oxygenation (ECMO), ICU admission and mortality due to COVID-19 infection were analyzed using logistic regression models. Results: Among patients confirmed COVID-19 between January 2020 and February 2022, 6627 of AIRD patients and 6627 propensity score-matched the general population were identified from HIRA database. Mean age of AIRD patients and the general population with COVID-19 infection was 52.45 and 52.43 years, respectively. Female were 68.2 % in each group. AIRD patients were not significantly higher risk of supplementary oxygen therapy (adjusted OR 0.94, 95% CI: 0.83-1.07 (adjusted P value = 0.34)), mechanical ventilator (adjusted OR 1.03, 95% CI: 0.75-1.40 (adjusted P value = 0.88)), CPR (adjusted OR 1.05, 95% CI: 0.58-1.91 (adjusted P value = 0.88)), or ECMO (adjusted OR 1.20, 95% CI: 0.52-2.78 (adjusted P value = 0.67)), ICU admission (adjusted OR 1.04, 95% CI: 0.85-1.36 (adjusted P value = 0.73)) and mortality (adjusted OR 0.94, 95% CI: 0.70-1.28 (adjusted P value = 0.70)) due to COVID-19 infection compared to the general population after adjusting age, sex, comorbidities and medication. Conclusion: Patients with AIRD dose not showed significantly increased risk of poor outcome of COVID-19 compared to the general population. REFERENCES: NIL. Acknowledgements: NIL. Disclosure of Interests: None declared.